Sam Davis, JD

Chief Business Officer, General Counsel & Corporate Secretary at Scipher Medicine
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Los Angeles Metropolitan Area
Languages
  • English Native or bilingual proficiency
  • Chinese Professional working proficiency
  • Persian Professional working proficiency
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Executive Training on the Biotechnology Industry
    Biotech Primer
    May, 2018
    - Nov, 2024
  • Member of the Massachusetts Bar
    Massachusetts Board of Bar Overseers

Experience

  • Scipher Medicine
    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Chief Business Officer, General Counsel & Corporate Secretary
      • Sep 2021 - Present

      As General Counsel, corporate secretary and member of the executive team of a venture-backed precision medicine biotech company focused on autoimmune and inflammatory disease, I lead patent and IP strategy, litigation, compliance, governance, advising the board and CEO, securities, all transactional matters, including an oversubscribed $120 million crossover round in 2022 (with Northpond, Khosla Ventures, Cowen, Neuberger Berman, aMoon, among others), an acquisition of a SAAS company in October… Show more As General Counsel, corporate secretary and member of the executive team of a venture-backed precision medicine biotech company focused on autoimmune and inflammatory disease, I lead patent and IP strategy, litigation, compliance, governance, advising the board and CEO, securities, all transactional matters, including an oversubscribed $120 million crossover round in 2022 (with Northpond, Khosla Ventures, Cowen, Neuberger Berman, aMoon, among others), an acquisition of a SAAS company in October 2022, multiple licenses and collaborations with biopharma, and payer strategy. My legal expertise and leadership play a significant role in shaping the company's growth and success. Ask me about Legal 2.0. As the Interim Chief Business Officer (starting in Nov. 2022), my role involves developing the company's therapeutics strategy by focusing on AI/ML target discovery collaborations, using Scipher's SPECTRA platform, and in-licensing clinical-stage therapeutic assets. I leverage my relationships in the life sciences ecosystem and help structure innovative deals, efficiently and with speed, that advance therapies through development, for the benefit of patients. Show less As General Counsel, corporate secretary and member of the executive team of a venture-backed precision medicine biotech company focused on autoimmune and inflammatory disease, I lead patent and IP strategy, litigation, compliance, governance, advising the board and CEO, securities, all transactional matters, including an oversubscribed $120 million crossover round in 2022 (with Northpond, Khosla Ventures, Cowen, Neuberger Berman, aMoon, among others), an acquisition of a SAAS company in October… Show more As General Counsel, corporate secretary and member of the executive team of a venture-backed precision medicine biotech company focused on autoimmune and inflammatory disease, I lead patent and IP strategy, litigation, compliance, governance, advising the board and CEO, securities, all transactional matters, including an oversubscribed $120 million crossover round in 2022 (with Northpond, Khosla Ventures, Cowen, Neuberger Berman, aMoon, among others), an acquisition of a SAAS company in October 2022, multiple licenses and collaborations with biopharma, and payer strategy. My legal expertise and leadership play a significant role in shaping the company's growth and success. Ask me about Legal 2.0. As the Interim Chief Business Officer (starting in Nov. 2022), my role involves developing the company's therapeutics strategy by focusing on AI/ML target discovery collaborations, using Scipher's SPECTRA platform, and in-licensing clinical-stage therapeutic assets. I leverage my relationships in the life sciences ecosystem and help structure innovative deals, efficiently and with speed, that advance therapies through development, for the benefit of patients. Show less

  • 3.0 Life Sciences
    • Global
    • Managing Partner
      • Jun 2023 - Present

      10X Business Development & Corporate Strategy 10X Business Development & Corporate Strategy

  • EQRx
    • United States
    • Biotechnology Research
    • 100 - 200 Employee
    • Vice President of Legal Affairs, Associate General Counsel
      • Aug 2020 - Sep 2021

      First legal hire for EQRx, in a leadership capacity, I reported directly to the CEO, and led all transactional matters, including a $500+ million Series B crossover round, a record-breaking $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, 10 license and collaborations, all agreements with payers/payors and health systems, all clinical and commercial agreements, managing the legal budget, led patent strategy, assisted with HR matters, and… Show more First legal hire for EQRx, in a leadership capacity, I reported directly to the CEO, and led all transactional matters, including a $500+ million Series B crossover round, a record-breaking $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, 10 license and collaborations, all agreements with payers/payors and health systems, all clinical and commercial agreements, managing the legal budget, led patent strategy, assisted with HR matters, and founded of Modern Vision Legal. Show less First legal hire for EQRx, in a leadership capacity, I reported directly to the CEO, and led all transactional matters, including a $500+ million Series B crossover round, a record-breaking $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, 10 license and collaborations, all agreements with payers/payors and health systems, all clinical and commercial agreements, managing the legal budget, led patent strategy, assisted with HR matters, and… Show more First legal hire for EQRx, in a leadership capacity, I reported directly to the CEO, and led all transactional matters, including a $500+ million Series B crossover round, a record-breaking $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, 10 license and collaborations, all agreements with payers/payors and health systems, all clinical and commercial agreements, managing the legal budget, led patent strategy, assisted with HR matters, and founded of Modern Vision Legal. Show less

  • McDermott Will & Emery
    • United States
    • Law Practice
    • 700 & Above Employee
    • Senior Associate, Corporate and Life Sciences Practice
      • Jun 2019 - Jul 2020

      Corporate, M&A, Private Equity, Emerging Companies and Venture Capital | Life Sciences | License & Collaboration | China Transactions | Founder of McDermott Rise https://mcdermottrise.mwe.com https://www.mwe.com/alumni/spotlight/sam-davis/ Representative clients: Ampersand Capital, Merck KGaA, Simcere Pharma, Scipher Medicine, Anthro Ventures. Corporate, M&A, Private Equity, Emerging Companies and Venture Capital | Life Sciences | License & Collaboration | China Transactions | Founder of McDermott Rise https://mcdermottrise.mwe.com https://www.mwe.com/alumni/spotlight/sam-davis/ Representative clients: Ampersand Capital, Merck KGaA, Simcere Pharma, Scipher Medicine, Anthro Ventures.

  • Goodwin
    • United States
    • Law Practice
    • 700 & Above Employee
    • Senior Associate, Technology and Life Sciences Practice
      • Aug 2017 - Jun 2019

      Corporate | Life Sciences Representative clients: Thrive Earlier Detection, FMI (Foundation Medicine), Teva, Scholar Rock, Ikena Oncology, and both the funds and the portfolio companies of Atlas Venture, Deerfield Management, Third Rock Ventures, SV Life Sciences, DDF, and others. Corporate | Life Sciences Representative clients: Thrive Earlier Detection, FMI (Foundation Medicine), Teva, Scholar Rock, Ikena Oncology, and both the funds and the portfolio companies of Atlas Venture, Deerfield Management, Third Rock Ventures, SV Life Sciences, DDF, and others.

  • Davis Malm
    • United States
    • Law Practice
    • 1 - 100 Employee
    • Associate
      • May 2015 - Aug 2017

      Corporate | Life Sciences & Technology Transactions Corporate | Life Sciences & Technology Transactions

  • ClinicalBox Inc.
    • United States
    • Medical Practices
    • 1 - 100 Employee
    • Strategic Advisor
      • Dec 2011 - Aug 2017

      https://www.clinicalbox.com https://www.clinicalbox.com

  • Winston & Strawn LLP
    • United States
    • Law Practice
    • 700 & Above Employee
    • Associate
      • 2014 - 2015

      Cross-border M&A, JVs, and commercial transactions Cross-border M&A, JVs, and commercial transactions

  • Sheppard Mullin Richter & Hampton LLP
    • United States
    • Law Practice
    • 700 & Above Employee
    • Associate
      • 2013 - 2014

      Cross-border M&A, VC & PE Cross-border M&A, VC & PE

  • Legal Services Center of Harvard Law School
    • United States
    • Legal Services
    • 1 - 100 Employee
    • Student Fellow
      • 2009 - 2010

      Under SJC Rule 3:03, represented pro-bono clients in Federal administrative appeals for disability benefits. Under SJC Rule 3:03, represented pro-bono clients in Federal administrative appeals for disability benefits.

Education

  • Syracuse University College of Law
    Doctor of Law (J.D.), Law
  • Shanghai Jiao Tong University
    Chinese Studies
  • University of Massachusetts Boston
    Bachelor of Science (B.S.), Magna Cum Laude, Business

Community

You need to have a working account to view this content. Click here to join now